Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Is there appetite after GLP-1 and PACAP?

J Christophe1

  • 1Department of General and Human Biochemistry, Université Libre de Bruxelles, Brussels, Belgium.

Annals of the New York Academy of Sciences
|February 3, 1999
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Virus-induced cancers: interplay between genetics and environment].

Revue medicale de Liege·2012
Same author

[Molecular endocrinology of hereditary obesity].

Bulletin et memoires de l'Academie royale de medecine de Belgique·1997
Same author

Glucagon and its receptor in various tissues.

Annals of the New York Academy of Sciences·1996
Same author

Glucagon receptors: from genetic structure and expression to effector coupling and biological responses.

Biochimica et biophysica acta·1995
Same author

Pancreatic tumoral cell line AR42J: an amphicrine model.

The American journal of physiology·1994
Same author

Characterization of ocular receptors for pituitary adenylate cyclase activating polypeptide (PACAP) and their coupling to adenylate cyclase.

Experimental eye research·1994
Same journal

Multiomics Profiling During Autoimmune Demyelination Highlights a Complex Regulatory Role for Ataxin-1 in B Cells.

Annals of the New York Academy of Sciences·2026
Same journal

Global Trends in Light Pollution and Their Relationship With Socioeconomic Factors.

Annals of the New York Academy of Sciences·2026
Same journal

Wired for Corruption: Inter-Brain Synchrony Encodes Bribery-Related Value Information and Predicts Bribery Agreement.

Annals of the New York Academy of Sciences·2026
Same journal

LM-YOLO: A Lightweight Multi-Scale Enhanced Model for Forest Smoke Detection Using Unmanned Aerial Vehicles.

Annals of the New York Academy of Sciences·2026
Same journal

Polyrhythm Perception and Production: A Scoping Review.

Annals of the New York Academy of Sciences·2026
Same journal

DARTS-CNN-BiLSTM: Intelligent Fault Diagnosis for Computer Numerical Control Machine Tool Feed System.

Annals of the New York Academy of Sciences·2026
See all related articles

New anti-obesity drugs require enhanced hypothalamic satiety signaling and NPY antagonism. Glucagon-like peptide-1 (GLP-1) and Pituitary adenylate cyclase-activating polypeptide (PACAP) show potential, but PACAP

Area of Science:

  • Neuroendocrinology
  • Obesity Research
  • Pharmacology

Background:

  • Current anti-obesity pharmacologic tools are largely ineffective.
  • Effective obesity treatments must enhance hypothalamic satiety sensitivity to leptin and antagonize Neuropeptide Y (NPY).
  • Investigating peptide analogs like NPY-5 antagonists and various agonists is ongoing.

Purpose of the Study:

  • To evaluate the potential roles of Glucagon-like peptide-1 (GLP-1) and Pituitary adenylate cyclase-activating polypeptide (PACAP) in obesity treatment.
  • To explore GLP-1 and PACAP interactions within key hypothalamic nuclei involved in appetite regulation.

Main Methods:

  • Examining GLP-1 receptor distribution in hypothalamic nuclei (ARC, PVN, VMN, SON) and its association with GLUT-2 and glucokinase.
  • Investigating PACAP presence in hypothalamic areas (ARC, PVN, SCH) and its receptor's signaling pathways (cAMP, inositol triphosphate).

Related Experiment Videos

  • Assessing the effects of GLP-1 and PACAP on food intake, insulin secretion, and neuronal activation (c-fos).

    • Main Results:

    • GLP-1 receptors are located in key hypothalamic satiety centers, and GLP-1 reduces food intake and induces c-fos expression in the ARC.
    • PACAP is present in relevant hypothalamic areas and may antagonize NPY-induced feeding and hyperinsulinemia.
    • PACAP also activates irrelevant neuroendocrine, autonomic, and circadian functions, posing challenges for its therapeutic use.

    Conclusions:

    • GLP-1 shows promise as a therapeutic agent for obesity due to its effects on hypothalamic satiety centers.
    • PACAP's broader neuroendocrine and autonomic effects make it a less suitable candidate for obesity treatment compared to GLP-1.
    • Further research is needed to fully elucidate the therapeutic potential and limitations of these peptides in obesity management.